Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 99-103

  Cook, Gary J R ^a,b   Houston, Stephen ^a   Barrington, Sally F ^a   Fogelman, Ignac ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

18F fluorodeoxyglucose PET; HL91; Technetium 99m; Tumor hypoxia

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UPENAZIME TC 99M;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXEMIA; ISOTOPE LABELING; LUNG CARCINOMA; LYMPHOMA; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE SARCOMA; THYROID CARCINOMA; TUMOR LOCALIZATION;

AGED; CELL HYPOXIA; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; OXIMES; PILOT PROJECTS; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031929644     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gatenby RA, Coia LR, Richter MP, et al. Oxygen tension in human tumours: in vivo mapping using CT-guided probes. Radiology 1985;156:211-214.
2. 2 measurements. Cancer Res 1991;51:6098-6102.
3. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship in outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-838.
4. Chapman JD. Hypoxic sensitizers: implications for radiation therapy N Engl J Med 1979;301:1429-1432.
5. Henk JM, Smith CS. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet 1977;2:104-105.
6. 2 tension measurements. Cancer Res 1991;51:3316-3322.
7. Chapman JD. Measurement of tumour hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiotherap Oncol 1991;20:13-19.
8. Okunieff PG, McFarland E, Rummeny E, et al. Effects of oxygen on the metabolism of murine tumours using in vivo phosphorus-31 NMR. Am J Clin Oncol 1987;10:475-482.
9. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-280.
10. Rasey JS, Kok WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumour hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-991.
11. Archer CM, Edwards B, Kelly JD, King AC, Burke JF, Riley ALM. Technetium labelled agents for imaging tissue hypoxia in vivo. In: Nicolini M, Bandoli G, Mazzi U, eds. Proceedings of the fourth international symposium on technetium in chemistry and nuclear medicine. 1995:535-539.
12. Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine 18 misonidazole: a marker of hypoxic myocardium. J Nucl Med 1989;30: 351-358.
13. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90-95.
14. Okada RD, Nguyen KN, Strauss HW, Johnson G. Effects of low flow and hypoxia on myocardial retention of technetium-99m BMS 181321. Eur J Nucl Med 1996;23:443-447.
15. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-1632.
16. Froudarakis M, Fournel P, Burgard G, et al. Bronchial carcinoids. A review of 22 cases. Oncology 1996;53:153-158.